The U.S. Food and Drug Administration is alerting consumers to Meridian Medical Technologies’ voluntary recall of 13 lots of Mylan’s EpiPen and EpiPen Jr (epinephrine injection) Auto-Injector products used for emergency treatment of severe allergic reactions. This recall is due to the potential that these devices may contain a defective part that may result in the devices’ failure to activate. The recalled product was manufactured by Meridian Medical Technologies and distributed by Mylan Specialty.
FDA alerts consumers of nationwide voluntary recall of EpiPen and EpiPen Jr
The U.S. Food and Drug Administration is alerting consumers to Meridian Medical Technologies’ voluntary recall of 13 lots of Mylan’s EpiPen and EpiPen Jr (epinephrine injection) Auto-Injector products used for emergency treatment of severe allergic reactions. This recall is due to the potential that these devices may contain a defective part that may result in the devices’ failure to activate. The recalled product was manufactured by Meridian Medical Technologies and distributed by Mylan Specialty.
Lifestyle Evolution Voluntarily Recalls One Shift of NuGo Slim Crunchy Peanut Butter
The recall is only for Lot B16119A. No other products are affected. Lifestyle Evolution is voluntarily recalling one shift of NuGo Slim Crunchy Peanut Butter nutrition bars. In isolated cases, a product with milk allergen was incorrectly packaged into Slim Crunchy Peanut Butter wrappers and cartons. The NuGo Slim Crunchy Peanut Butter wrapper does not list milk as an allergen.
Read The Complete Story!
URGENT: Envy Me Is Recalling LaBri’s Body Health Atomic 60 Capsules Due To Undeclared Sibutramine
Envy Me is recalling LaBri’s Body Health Atomic, dietary supplement marketed for weight loss, sold in 60 capsule, plastic bottles. The recall includes all lot codes, manufacturing codes and expiration dates.
The United States Food and Drug Administration has analyzed samples of La Bri’s Body Health Atomic and found it to contain the undeclared ingredient sibutramine.
FDA approves new drug to treat multiple sclerosis
On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). This is the first drug approved by the FDA for PPMS. Ocrevus is an intravenous infusion given by a health care professional.
Sunshine Bakery Announces Voluntary Recall of Cassava Cake And Mixed Nut Mooncake
Sunshine Bakery of Alhambra, CA is voluntarily recalling CASSAVA CAKE AND MIXED NUT MOONCAKE with best by dates of 3/24/2017. The products were sold to retail stores in 2/24/2017.
FDA approves new eczema drug Dupixent
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Allergy Alert Issued by Whole Foods Market in Hadley, Massachusetts For Undeclared Walnuts in Banana Chocolate Chip Muffins
Whole Foods Market® in Hadley, Massachusetts is issuing an allergy alert to recall six-packs of Banana Chocolate Chip Muffins due to an in-store labeling error.
Allergy Alert Issued by Whole Foods Market in Hadley, Massachusetts For Undeclared Walnuts in Banana Chocolate Chip Muffins
Whole Foods Market® in Hadley, Massachusetts is issuing an allergy alert to recall six-packs of Banana Chocolate Chip Muffins due to an in-store labeling error.
FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.